Literature DB >> 19587131

Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein.

Joan E Adamo1, Clement A Meseda1, Jerry P Weir1, Michael J Merchlinsky1.   

Abstract

Vaccination with Dryvax elicits a broad humoral response against many viral proteins. Human vaccinia immune globulin was used to screen the secreted proteins from cells infected with Dryvax or the candidate smallpox vaccine LC16m8 to determine whether the protective humoral response included antibodies against secreted viral proteins. Many proteins were detected, with the primary band corresponding to a band of 28 or 30 kDa in cells infected with Dryvax or LC16m8, respectively. This was identified as the vaccinia virus complement protein (VCP), which migrated more slowly in LC16m8-infected cells due to post-translational glycosylation. Vaccinia virus deleted in VCP, vVCPko, protected mice from a lethal intranasal challenge of vaccinia Western Reserve strain. Mice vaccinated with purified VCP demonstrated a strong humoral response, but were not protected against a moderate lethal challenge of vaccinia virus, suggesting that the humoral response against VCP is not critical for protection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587131      PMCID: PMC2888316          DOI: 10.1099/vir.0.008474-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates.

Authors:  B P Morgan
Journal:  Methods Mol Biol       Date:  2000

2.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

Authors:  A Vassilev; K J Kaneko; H Shu; Y Zhao; M L DePamphilis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

3.  Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Authors:  Cyril Empig; Julie R Kenner; Marcel Perret-Gentil; Bryan E Youree; Edward Bell; Allen Chen; Marc Gurwith; Keith Higgins; Michael Lock; Amanda D Rice; Jill Schriewer; Faruk Sinangil; Elizabeth White; R Mark Buller; Terence S Dermody; Stuart N Isaacs; Richard W Moyer
Journal:  Vaccine       Date:  2006-04-24       Impact factor: 3.641

4.  Vaccinia virus WR gene A5L is required for morphogenesis of mature virions.

Authors:  O Williams; E J Wolffe; A S Weisberg; M Merchlinsky
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.

Authors:  Agnes Jones-Trower; Alonzo Garcia; Clement A Meseda; Yong He; Carol Weiss; Arunima Kumar; Jerry P Weir; Michael Merchlinsky
Journal:  Virology       Date:  2005-09-13       Impact factor: 3.616

6.  Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant.

Authors:  G J Kotwal; B Moss
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

7.  Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery.

Authors:  D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

8.  Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.

Authors:  Stuart N Isaacs; Emelia Argyropoulos; Georgia Sfyroera; Shamim Mohammad; John D Lambris
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 9.  Variola virus immune evasion proteins.

Authors:  Lance R Dunlop; Katherine A Oehlberg; Jeremy J Reid; Dilek Avci; Ariella M Rosengard
Journal:  Microbes Infect       Date:  2003-09       Impact factor: 2.700

10.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.

Authors:  S N Isaacs; G J Kotwal; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

View more
  8 in total

1.  Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus.

Authors:  Xiangzhi Meng; Youmin Zhong; Addie Embry; Bo Yan; Shan Lu; Guangming Zhong; Yan Xiang
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

2.  Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Authors:  Elizabeth A Moulton; Paula Bertram; Nanhai Chen; R Mark L Buller; John P Atkinson
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.

Authors:  Joseph W Golden; Jay W Hooper
Journal:  Clin Vaccine Immunol       Date:  2010-09-15

4.  Influence of glycosylation and oligomerization of vaccinia virus complement control protein on level and pattern of functional activity and immunogenicity.

Authors:  Girish J Kotwal
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

5.  Capturing the natural diversity of the human antibody response against vaccinia virus.

Authors:  Johan Lantto; Margit Haahr Hansen; Søren Kofoed Rasmussen; Lucilla Steinaa; Tine R Poulsen; Jackie Duggan; Mike Dennis; Irene Naylor; Linda Easterbrook; Søren Bregenholt; John Haurum; Allan Jensen
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

6.  Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.

Authors:  Clement A Meseda; Jordan Kuhn; Vajini Atukorale; Joseph Campbell; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

7.  Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.

Authors:  Yuhong Xiao; Stuart N Isaacs
Journal:  Viruses       Date:  2010-10       Impact factor: 5.048

8.  Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.

Authors:  Clement A Meseda; Joseph Campbell; Arunima Kumar; Alonzo D Garcia; Michael Merchlinsky; Jerry P Weir
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.